Page 32 - Read Online

Page 12 of 16 Moreno-Martínez et al. Rare Dis Orphan Drugs J 2024;3:9 https://dx.doi.org/10.20517/rdodj.2023.51

Survey. Eur J Clin Invest 2004;34:236-42. DOI PubMed
4. AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales). [Evaluation of patients
with Fabry disease in Argentina]. Medicina 2010;70:37-43. (in Spanish). PubMed
5. Giugliani R, Niu D, Ramaswami U, et al. A 15-year perspective of the fabry outcome survey. J Inborn Errors Metab Screen
2016;4:e160041. DOI
6. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum
Genet 2006;79:31-40. DOI PubMed PMC
7. Lin HY, Chong KW, Hsu JH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the
Taiwan Chinese population. Circ Cardiovasc Genet 2009;2:450-6. DOI PubMed
8. Marchesoni CL, Roa N, Pardal AM, et al. Misdiagnosis in Fabry disease. J Pediatr 2010;156:828-31. DOI PubMed
9. Reisin R, Perrin A, García-Pavía P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract 2017;71:e12914.
DOI PubMed
10. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry’s disease with manifestations confined to the
myocardium. N Engl J Med 1991;324:395-9. DOI PubMed
11. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal
variant” phenotype. Kidney Int 2003;64:801-7. DOI PubMed
12. Rolfs A, Fazekas F, Grittner U, et al; Stroke in Young Fabry Patients (sifap) Investigators. Acute cerebrovascular disease in the
young: the Stroke in Young Fabry Patients study. Stroke 2013;44:340-9. DOI PubMed
13. Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab
2018;124:189-203. DOI PubMed
14. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA
2001;285:2743-9. DOI PubMed
15. Eng CM, Guffon N, Wilcox WR, et al; International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant
human alpha-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9-16. DOI PubMed
16. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J
Med 2016;375:545-55. DOI PubMed
17. Schiffmann R. Fabry disease. Pharmacol Ther 2009;122:65-77. DOI PubMed
18. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258-63. DOI
PubMed
19. Joly DA, Grünfeld JP. 3-Nitrotyrosine as a biomarker for vascular involvement in Fabry disease. Kidney Int 2014;86:5-7. DOI
PubMed
20. Shu L, Vivekanandan-Giri A, Pennathur S, et al. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.
Kidney Int 2014;86:58-66. DOI PubMed PMC
21. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral
autoregulation in patients with Fabry disease. J Neurol 2004;251:564-70. DOI PubMed
22. Moore DF, Altarescu G, Ling GSF, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme
replacement. Stroke 2002;33:525-31. DOI PubMed
23. Biancini GB, Vanzin CS, Rodrigues DB, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry
patients treated with enzyme replacement therapy. Biochim Biophys Acta 2012;1822:226-32. DOI PubMed
24. Simoncini C, Torri S, Montano V, et al. Oxidative stress biomarkers in Fabry disease: is there a room for them? J Neurol
2020;267:3741-52. DOI PubMed PMC
25. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab 2017;122:19-27.
DOI PubMed
26. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J
Exp Med 1998;188:1529-34. DOI PubMed PMC
27. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by
CD1d tetramer staining. J Exp Med 2002;195:625-36. DOI PubMed PMC
-
+
+
28. O’Reilly V, Zeng SG, Bricard G, et al. Distinct and overlapping effector functions of expanded human CD4 , CD8α and CD4 CD8α -
invariant natural killer T cells. PLoS One 2011;6:e28648. DOI PubMed PMC
29. Reisin RC, Rozenfeld P, Bonardo P. Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis.
Med Hypotheses 2020;144:110282. DOI PubMed PMC
30. Schiffmann R. Fabry disease. Handb Clin Neurol 2015;132:231-48. DOI PubMed
31. Biancini GB, Jacques CE, Hammerschmidt T, et al. Biomolecules damage and redox status abnormalities in Fabry patients before and
during enzyme replacement therapy. Clin Chim Acta 2016;461:41-6. DOI PubMed
32. Kang JJ, Kaissarian NM, Desch KC, et al. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry
disease. Kidney Int 2019;95:149-59. DOI PubMed PMC
33. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol
2000;47:229-33. PubMed
34. Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule